Literature DB >> 6822615

Cerebral blood flow studied by Xenon-133 inhalation technique in parkinsonism: loss of hyperfrontal pattern.

A Bès, A Güell, N Fabre, P Dupui, G Victor, G Géraud.   

Abstract

Cerebral blood flow (grey matter flow) in parkinsonism requires further investigation. The noninvasive method of 133Xe inhalation permits study of larger numbers of subjects than previously used invasive techniques such as the intracarotid 133Xe injection method. Measurements were made in this laboratory in 30 subjects having Parkinson's disease. Mean hemispheric blood flow (F1) values were 70.4 +/- 9.3 ml/100 g/min, compared to 76.3 for a group of age-matched normal subjects, which is a decrease of -7.8%. The most striking difference was the loss of the "hyperfrontal distribution" in parkinsonism. The prefrontal F1 values were only 1.8% greater than the hemisphere grey matter flow, compared with 8.5% in controls of a similar age group.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6822615     DOI: 10.1038/jcbfm.1983.3

Source DB:  PubMed          Journal:  J Cereb Blood Flow Metab        ISSN: 0271-678X            Impact factor:   6.200


  5 in total

1.  Prefrontal cortical blood flow and cognitive function in Huntington's disease.

Authors:  D R Weinberger; K F Berman; M Iadarola; N Driesen; R F Zec
Journal:  J Neurol Neurosurg Psychiatry       Date:  1988-01       Impact factor: 10.154

Review 2.  N200 and P300 component changes in Parkinson's disease: a meta-analysis.

Authors:  Hui Xu; Lihua Gu; Shiyao Zhang; Yuchen Wu; Xiaojin Wei; Caiyan Wang; Yuhan Xu; Yijing Guo
Journal:  Neurol Sci       Date:  2022-08-18       Impact factor: 3.830

3.  Technetium-99m hexamethylpropylene amine oxime single photon emission tomography of the brain in early Parkinson's disease: correlation with dementia and lateralization.

Authors:  S J Wang; R S Liu; H C Liu; K N Lin; D E Shan; K K Liao; J L Fuh; L S Lee
Journal:  Eur J Nucl Med       Date:  1993-04

4.  Local cerebral glucose utilisation in treated and untreated patients with Parkinson's disease.

Authors:  D Rougemont; J C Baron; P Collard; P Bustany; D Comar; Y Agid
Journal:  J Neurol Neurosurg Psychiatry       Date:  1984-08       Impact factor: 10.154

5.  Three-dimensional surface display of brain perfusion with 123I-IMP in Parkinson's disease.

Authors:  H Tachibana; K Kawabata; Y Tomino; M Sugita; M Fukuchi
Journal:  Neuroradiology       Date:  1994-05       Impact factor: 2.804

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.